Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 224,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "9c350ec3-b0f5-4a73-bdd6-a9d9d95abfb0",
"title": "Entourage Health Q1 Revenue Declines 4.8% YoY, What About Adjusted EBITDA? - Entourage Health (OTC:ETRGF)",
"description": "Entourage Health Corp. (OTCQX: ETRGF) (TSX-V:ENTG) (FSE:4WE) released its financial results for the three months ended March 31, 2023.",
"keywords": "",
"snippet": "Entourage Health Corp. ETRGF ENTG (FSE:4WE) released its financial results for the three months ended March 31, 2023. revealing net revenue of CA$11.8 million, ...",
"url": "https://www.benzinga.com/markets/cannabis/23/05/32624469/entourage-health-q1-revenue-declines-4-8-yoy-what-about-adjusted-ebitda",
"image_url": "https://cdn.benzinga.com/files/images/story/2023/05/30/finance_and_marijuana_kindel_media_by_pexels.jpg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2023-05-30T13:22:51.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "ENTG.V",
"name": "ENTOURAGE HEALTH CORP",
"exchange": "TSXV",
"exchange_long": "TSX Venture Exchange",
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.69815,
"sentiment_score": -0.123267,
"highlights": [
{
"highlight": "<em>Entourage</em> <em>Health</em> <em>Corp</em>. ETRGF ENTG (FSE:4WE) released its financial results for the three months ended March 31, 2023. revealing net revenue of CA$11.8 million, ($8.7 million) a decrease of 4.8% compared to CA$12.4 million in Q1 2022.\n\nQ1 2023 Financial Highlights\n\nGross profit was CA$4.0 million compared to CA$1.9 million in Q1 2022.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Photo: Benzinga edit with photo by Kindel Media on Pexels\n\nRelated News\n\n<em>Entourage</em> <em>Health</em> Reports FY22 Revenue of $54.5M, Loss Of $123.15M",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Entourage</em> <em>Health</em> Q1 Revenue Declines 4.8% YoY, What About Adjusted EBITDA? - <em>Entourage</em> <em>Health</em> (OTC:ETRGF)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "e09adff2-2aa3-49c4-8195-780fe44cebdc",
"title": "T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History By Investing.com",
"description": "T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History",
"keywords": "",
"snippet": "Published May 30, 2023 09:03AM ET\n\nT2 Biosystems (TTOO) Announces Second Largest Sepsis-Driven Instrument Sale in Company History\n\nTTOO -11.42% Add to/Remove fr...",
"url": "https://www.investing.com/news/assorted/t2-biosystems-announces-second-largest-sepsisdriven-instrument-sale-in-company-history-432SI-3093926",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2023-05-30T13:05:02.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "TTOO",
"name": "T2 Biosystems, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 92.56511,
"sentiment_score": 0.210575,
"highlights": [
{
"highlight": "Published May 30, 2023 09:03AM ET\n\n<em>T2</em> <em>Biosystems</em> (TTOO) Announces Second Largest Sepsis-Driven Instrument Sale in Company History\n\nTTOO -11.42% Add to/Remove from Watchlist\n\n<em>T2</em> <em>Biosystems</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em>’ distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels that are expected to be deployed in selected hospitals across Poland.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "“We are thrilled with this order and look forward to working closely with our distribution partner, Biomedica Poland, to deliver our state-of-the-art sepsis diagnostic products to hospitals across Poland,” stated John Sperzel, Chairman and CEO of <em>T2</em> <em>Biosystems</em>.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em> Announces Second Largest Sepsis-Driven Instrument Sale in Company History By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "7f892fa2-8988-4dcd-adac-f6df05067208",
"title": "T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History",
"description": "LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and...",
"keywords": "Nasdaq:TTOO, T2 Biosystems, Inc.",
"snippet": "LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678417/32489/en/T2-Biosystems-Announces-Second-Largest-Sepsis-Driven-Instrument-Sale-in-Company-History.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/21ce43b1-81a5-42af-8c47-c2df2e179d21",
"language": "en",
"published_at": "2023-05-30T13:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "TTOO",
"name": "T2 Biosystems, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 92.108604,
"sentiment_score": 0.364243,
"highlights": [
{
"highlight": "., May 30, 2023 (GLOBE NEWSWIRE) -- <em>T2</em> <em>Biosystems</em>, <em>Inc</em>. (<em>NASDAQ:TTOO</em>), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in Company history.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em>’ distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels that are expected to be deployed in selected hospitals across Poland.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "“We are thrilled with this order and look forward to working closely with our distribution partner, Biomedica Poland, to deliver our state-of-the-art sepsis diagnostic products to hospitals across Poland,” stated John Sperzel, Chairman and CEO of <em>T2</em> <em>Biosystems</em>.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>T2</em> <em>Biosystems</em>\n\n<em>T2</em> <em>Biosystems</em>, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before.",
"sentiment": 0.9584,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em>’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em> has an active pipeline of future products, including the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.",
"sentiment": 0.749,
"highlighted_in": "main_text"
},
{
"highlight": "<em>T2</em> <em>Biosystems</em> Announces Second Largest Sepsis-Driven Instrument Sale in Company History",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "f44a761f-d419-4f9d-b4f6-9bc905893834",
"title": "Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023",
"description": "/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a growing pipeline,...",
"keywords": "Moleculin Biotech, Inc., Health Care & Hospitals, Medical Pharmaceuticals, Biotechnology",
"snippet": "- Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so\n\nHOUSTON, May 30, 2023 /PRNewswire/...",
"url": "https://www.prnewswire.com/news-releases/moleculin-announces-adjournment-of-2023-annual-meeting-to-june-15-2023-301836778.html",
"image_url": "https://mma.prnewswire.com/media/959635/Moleculin_Biotech_Inc_Logo.jpg?p=facebook",
"language": "en",
"published_at": "2023-05-30T13:05:00.000000Z",
"source": "prnewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MBRX",
"name": "Moleculin Biotech, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 83.753845,
"sentiment_score": 0.2061,
"highlights": [
{
"highlight": "- Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so\n\nHOUSTON, May 30, 2023 /PRNewswire/ -- <em>Moleculin</em> <em>Biotech</em>, <em>Inc</em>., (<em>Nasdaq</em>: <em>MBRX</em>) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Moleculin</em> <em>Biotech</em>, <em>Inc</em>.\n\n<em>Moleculin</em> <em>Biotech</em>, <em>Inc</em>. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Contact:\n\nJTC Team, LLC\n\nJenene Thomas\n\n(833) 475-8247\n\n[email protected]\n\nSOURCE <em>Moleculin</em> <em>Biotech</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "847393cf-3fa2-400f-bd31-eb9a0a1321ce",
"title": "Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting",
"description": "TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage...",
"keywords": "Nasdaq:CWBR, CohBar, Inc.",
"snippet": "TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotec...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678315/0/en/Morphogenesis-Inc-and-CohBar-Inc-Announce-Acceptance-of-Abstract-for-Poster-Presentation-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/17ec4007-256a-45a3-bb01-44b343442386",
"language": "en",
"published_at": "2023-05-30T12:05:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "CWBR",
"name": "CohBar, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 92.20988,
"sentiment_score": 0.188009,
"highlights": [
{
"highlight": "(“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and <em>CohBar</em>, <em>Inc</em>.",
"sentiment": -0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>CWBR</em>) (“<em>CohBar</em>”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>CohBar</em>\n\n<em>CohBar</em> (<em>NASDAQ</em>: <em>CWBR</em>) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Additional Information About the Proposed Transaction for Investors and Stockholders\n\nIn connection with the proposed transaction between <em>CohBar</em> and Morphogenesis (the “Proposed Transaction”), <em>CohBar</em> intends to file relevant materials with the U.S.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that will contain a proxy statement/prospectus of <em>CohBar</em>. This press release is not a substitute for the registration statement or for any other document that <em>CohBar</em> may file with the SEC in connection with the Proposed Transaction.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>COHBAR</em> URGES INVESTORS AND STOCKHOLDERS TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT <em>COHBAR</em>",
"sentiment": 0.7649,
"highlighted_in": "main_text"
},
{
"highlight": "Investors and stockholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed by <em>CohBar</em> with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, investors and stockholders should note that <em>CohBar</em> communicates with investors and the public using its website (www.cohbar.com), including its investor relations website (https://cohbar.com/investors), where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by <em>CohBar</em> with the SEC, and",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Participants in the Solicitation\n\n<em>CohBar</em>, Morphogenesis and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from CohBar’s stockholders in connection with the Proposed Transaction.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Jenene Thomas\n\nJTC Team, LLC\n\[email protected]\n\n<em>CohBar</em>, <em>Inc</em>.\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Morphogenesis, Inc. and <em>CohBar</em>, <em>Inc</em>. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting",
"sentiment": 0.4588,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "180aea0d-4dff-4d76-9880-1a5173ca4222",
"title": "TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting",
"description": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development...",
"keywords": "Nasdaq:TCON, TRACON Pharmaceuticals, Inc.",
"snippet": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and com...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678275/10391/en/TRACON-Pharmaceuticals-Announces-Poster-Presentations-for-Envafolimab-and-TRC102-at-the-2023-ASCO-Annual-Meeting.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/7f258b4f-70ae-4962-a929-391f3c803329",
"language": "en",
"published_at": "2023-05-30T12:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "TCON",
"name": "TRACON Pharmaceuticals, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 75.91964,
"sentiment_score": 0.1591,
"highlights": [
{
"highlight": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- <em>TRACON</em> <em>Pharmaceuticals</em> (<em>NASDAQ</em>: <em>TCON</em>), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>TRACON</em> <em>Pharmaceuticals</em> Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "130ec790-ea02-4ef2-a325-5ea510b4fa62",
"title": "Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting",
"description": "ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a...",
"keywords": "Nasdaq:BNOX, Bionomics Ltd, BNC210, Biotech, PTSD, CNS, Social Anxiety",
"snippet": "ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage ...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678107/0/en/Bionomics-Announces-Upcoming-Poster-Presentation-at-the-American-Society-of-Clinical-Psychopharmacology-ASCP-Annual-Meeting.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/822aaa99-a2bd-4905-ab9c-07869668b7f7",
"language": "en",
"published_at": "2023-05-30T10:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.885917,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Beyond BNC210, Bionomics has a strategic partnership with <em>Merck</em> & <em>Co</em>., <em>Inc</em>. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BNOEF",
"name": "Bionomics Limited",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 53.860256,
"sentiment_score": -0.10365,
"highlights": [
{
"highlight": "., May 30, 2023 (GLOBE NEWSWIRE) -- <em>Bionomics</em> <em>Limited</em> (Nasdaq: BNOX | ASX: BNO) (<em>Bionomics</em> or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators for serious central nervous system (CNS) disorders with a high unmet medical need, today announced it will present data on BNC210 for the treatment of Social",
"sentiment": -0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "“PREVAIL’s results demonstrate BNC210’s differentiated profile and potential to address a pressing unmet need, as there are currently no rapid-acting, non-sedating, non-habit-forming therapies approved for the acute treatment of anxiety episodes in SAD,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of <em>Bionomics</em>.",
"sentiment": -0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Connor Bernstein\n\nVice President, Strategy\n\nand Corporate Development\n\n+1 (650) 524-5143\n\[email protected]\n\n\n\nInvestor Relations\n\nKevin Gardner\n\[email protected]\n\n\n\n\n\nAbout <em>Bionomics</em> <em>Limited</em>\n\n<em>Bionomics</em> (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Bionomics</em> is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).",
"sentiment": -0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "Beyond BNC210, <em>Bionomics</em> has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "www.bionomics.com.au\n\nForward-Looking Statements\n\n<em>Bionomics</em> cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The inclusion of forward-looking statements should not be regarded as a representation by <em>Bionomics</em> that any of its plans will be achieved.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and <em>Bionomics</em> undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Further information regarding these and other risks is included in <em>Bionomics</em>’ filings with the SEC, which are available from the SEC's website (www.sec.gov) and on <em>Bionomics</em>’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Bionomics</em> Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": "BCBA",
"exchange_long": "Buenos Aires Stock Exchange",
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 13.885437,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Beyond BNC210, Bionomics has a strategic partnership with <em>Merck</em> & <em>Co</em>., <em>Inc</em>. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": "SSE",
"exchange_long": "Santiago Stock Exchange",
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.885215,
"sentiment_score": 0.1779,
"highlights": [
{
"highlight": "Beyond BNC210, Bionomics has a strategic partnership with <em>Merck</em> & <em>Co</em>., <em>Inc</em>. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "6f54a8e6-e276-479b-9e1e-c02ffe87ece3",
"title": "Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency By Investing.com",
"description": "Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency",
"keywords": "",
"snippet": "Published May 30, 2023 09:02AM ET\n\nInhibrx (INBX) Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency\n\nINBX +4.91% ...",
"url": "https://www.investing.com/news/assorted/inhibrx-granted-fast-track-designation-for-inbrx101-for-the-treatment-of-alpha1-antitrypsin-deficiency-432SI-3093924",
"image_url": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
"language": "en",
"published_at": "2023-05-30T13:04:04.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "INBX",
"name": "Inhibrx, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 70.07631,
"sentiment_score": 0.3196,
"highlights": [
{
"highlight": "Published May 30, 2023 09:02AM ET\n\n<em>Inhibrx</em> (INBX) Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency\n\nINBX +4.91% Add to/Remove from Watchlist\n\n<em>Inhibrx</em>, <em>Inc</em>.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>INBX</em>), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that the U.S.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inhibrx</em> Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency By Investing.com",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "920894a3-6bfb-49cc-9178-d6e7ae969dbc",
"title": "Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference",
"description": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...",
"keywords": "Nasdaq:XGN, Exagen Inc., $XGN, Growth Conference, William Blair Conference, BIOTECHNOLOGY, Exagen Diagnostics, AVISE CTD",
"snippet": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in ...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678414/32920/en/Exagen-Inc-to-Participate-in-the-William-Blair-43rd-Annual-Growth-Stock-Conference.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/1008ba13-c3b0-4464-a6f3-60b9470aa25e",
"language": "en",
"published_at": "2023-05-30T13:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "XGN",
"name": "Exagen Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 113.2199,
"sentiment_score": 0.233175,
"highlights": [
{
"highlight": "SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- <em>Exagen</em> <em>Inc</em>. (<em>Nasdaq</em>: <em>XGN</em>), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43rd Annual Growth Stock Conference, which takes place June 6-8, 2023, in Chicago at the Loews Chicago Hotel.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Exagen</em> <em>Inc</em>.\n\n<em>Exagen</em> is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. <em>Exagen</em> is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys.",
"sentiment": 0.8658,
"highlighted_in": "main_text"
},
{
"highlight": "The goal at <em>Exagen</em> is to assist patients, physicians, and payors by enabling precision medicine. <em>Exagen</em> is located in San Diego County.\n\nFor more information, please visit Exagen.com and follow @ExagenInc on Twitter.",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "Forward Looking Statements\n\n<em>Exagen</em> cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "The inclusion of forward-looking statements should not be regarded as a representation by <em>Exagen</em> that any of its plans will be achieved.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and <em>Exagen</em> undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Relations\n\n<em>Exagen</em> <em>Inc</em>.\n\nRyan Douglas\n\[email protected]\n\n760.560.1525\n\nCompany\n\n<em>Exagen</em> <em>Inc</em>.\n\nKamal Adawi, Chief Financial Officer\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Exagen</em> <em>Inc</em>. to Participate in the William Blair 43rd Annual Growth Stock Conference",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b8f2db2e-a99c-467a-965e-08c46a550aad",
"title": "BioCardia: An Update And A Near-Term Catalyst (Rating Downgrade) (NASDAQ:BCDA)",
"description": "BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02. Check out my recommendation on BCDA stock.",
"keywords": "",
"snippet": "Mohammed Haneefa Nizamudeen\n\nI first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock. Si...",
"url": "https://seekingalpha.com/article/4608169-biocardia-an-update-and-a-near-term-catalyst",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359314170/image_1359314170.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2023-05-30T12:50:56.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "BCDA",
"name": "BioCardia, Inc.",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 87.63037,
"sentiment_score": 0.233433,
"highlights": [
{
"highlight": "Mohammed Haneefa Nizamudeen\n\nI first wrote about <em>BioCardia</em> (<em>NASDAQ:BCDA</em>) in June of 2021, explaining why I'd taken a speculative-sized position in the stock. Since then the share price is down (as it is with the majority of small cap biotechs), yet as I outline below the company has made significant progress in the interim.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BioCardia</em>\n\nBCDA has four therapeutic candidates and a patented drug delivery system (for delivering cells directly into the heart) in its current development pipeline.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BioCardia</em>: An Update And A Near-Term Catalyst (Rating Downgrade) (<em>NASDAQ:BCDA</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7aa6a4af-8b33-454a-858e-d2673986e19c",
"title": "SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP",
"description": "As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30,...",
"keywords": "Nasdaq:SPRC, SciSparc Ltd, Management, Restructuring, corporaterestructuring",
"snippet": "As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities\n\nTEL AVIV, Israel, May 30, 2023 (...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678385/0/en/SciSparc-Makes-Another-Step-Towards-Unlocking-Potential-Value-Appoints-New-Strategy-and-Business-Development-VP.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90",
"language": "en",
"published_at": "2023-05-30T12:40:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "SPRCY",
"name": "SciSparc Ltd.",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 52.868187,
"sentiment_score": 0.4111,
"highlights": [
{
"highlight": "Yaki Baranes will facilitate identifying new business opportunities\n\nTEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- <em>SciSparc</em> <em>Ltd</em>.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>SciSparc</em> <em>Ltd</em>. (Nasdaq: SPRC):\n\n<em>SciSparc</em> <em>Ltd</em>. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SPRCF",
"name": "SciSparc Ltd.",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 52.854683,
"sentiment_score": 0.4111,
"highlights": [
{
"highlight": "Yaki Baranes will facilitate identifying new business opportunities\n\nTEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- <em>SciSparc</em> <em>Ltd</em>.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>SciSparc</em> <em>Ltd</em>. (Nasdaq: SPRC):\n\n<em>SciSparc</em> <em>Ltd</em>. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "77c98c75-a998-48f5-a00f-0a46bab41489",
"title": "ChromaDex to Participate in the LD Micro Invitational XIII",
"description": "ChromaDex Corp. today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to... | May 30, 2023",
"keywords": "CHROMADEX CORPORATION stock exchange, news, information, press release, chromadex, today, announced, that, it, will, be, participating, at, the, 13th, annual, ld, micro, invitational, luxe, sunset, boulevard, california, on, june, event, is, expected | CDXC | US1710774076",
"snippet": "ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Califor...",
"url": "https://www.marketscreener.com/quote/stock/CHROMADEX-CORPORATION-27343156/news/ChromaDex-to-Participate-in-the-LD-Micro-Invitational-XIII-43989058/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2023-05-30T12:35:02.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "CDXC",
"name": "ChromaDex Corporation",
"exchange": "NASDAQ",
"exchange_long": "NASDAQ Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.039963,
"sentiment_score": 0.452514,
"highlights": [
{
"highlight": "<em>ChromaDex</em> Corp. (<em>NASDAQ:CDXC</em>) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ChromaDex</em> management will also attend virtual one-on-one meetings with institutional investors throughout the day. For those interested in having a meeting with <em>ChromaDex</em>, please visit www.ldmicro.com for more information.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "We invite interested parties to watch ChromaDex’s live presentation via this webcast link: <em>ChromaDex</em> Investor Presentation – LD Micro Invitational\n\nTo view ChromaDex’s profile, please use this link: http://www.ldmicro.com/profile/CDXC\n\nFor additional information on <em>ChromaDex</em>, visit www.chromadex.com.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>ChromaDex</em>:\n\n<em>ChromaDex</em> Corp. is a global bioscience company dedicated to healthy aging. The <em>ChromaDex</em> team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ChromaDex</em> is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ChromaDex</em> maintains a website at www.chromadex.com to which <em>ChromaDex</em> regularly posts copies of its press releases as well as additional and financial information about the Company.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230530005227/en/",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ChromaDex</em> to Participate in the LD Micro Invitational XIII",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "33480bfe-061b-4488-9672-c6ebecf9aea4",
"title": "Canopy Growth Corporation (CGC) And Indiva Inc. Announce Agreement",
"description": "CANOPY GROWTH AND INDIVA ANNOUNCE AGREEMENT TO POSITION WANA GUMMIES FOR CONTINUED…",
"keywords": "",
"snippet": "CANOPY GROWTH AND INDIVA ANNOUNCE AGREEMENT TO POSITION WANA GUMMIES FOR CONTINUED NORTH AMERICAN BRAND LEADERSHIP\n\nCanopy Growth Corporation (“Canopy Growth?...",
"url": "https://marijuanastocks.com/cgc-and-indiva-inc-announce-agreement/",
"image_url": "https://marijuanastocks.com/wp-content/uploads/2020/09/NEW-MJ-NEWS-PIC-.jpg",
"language": "en",
"published_at": "2023-05-30T12:31:23.000000Z",
"source": "marijuanastocks.com",
"relevance_score": null,
"entities": [
{
"symbol": "NDVA.V",
"name": "Indiva Limited",
"exchange": "TSXV",
"exchange_long": "TSX Venture Exchange",
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 70.35328,
"sentiment_score": 0.633418,
"highlights": [
{
"highlight": "CANOPY GROWTH AND <em>INDIVA</em> ANNOUNCE AGREEMENT TO POSITION WANA GUMMIES FOR CONTINUED NORTH AMERICAN BRAND LEADERSHIP\n\nCanopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC), a leading global cannabis company, and <em>Indiva</em> <em>Limited</em> (“<em>Indiva</em>”) (<em>TSXV:NDVA</em>), the leading Canadian producer of cannabis edibles and other cannabis",
"sentiment": 0.871,
"highlighted_in": "main_text"
},
{
"highlight": "Simultaneously, to support continuity of quality supply and aligned to Canopy Growth’s asset light strategy for sourcing of cannabis 2.0 formats, Canopy Growth and <em>Indiva</em> also entered into a contract manufacturing agreement (the “Manufacturing Agreement”), under which Canopy Growth will grant <em>Indiva</em> the exclusive right to manufacture and supply Wana",
"sentiment": 0.9393,
"highlighted_in": "main_text"
},
{
"highlight": "We expect this arrangement to be immediately accretive to Canopy Growth’s EBITDA, and we look forward to partnering with <em>Indiva</em> to further bolster Wana’s position as a leading edible brand in Canada.”",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We thank <em>Indiva</em> for all they have done to make Wana the top edible in Canada over the past three years1 and we are pleased that we will have the opportunity to continue to work with their great team in a production capacity.”",
"sentiment": 0.9201,
"highlighted_in": "main_text"
},
{
"highlight": "Transaction Terms\n\nAs consideration for <em>Indiva</em> entering into the Assignment Agreement and other related agreements in respect of the transactions described herein, <em>Indiva</em> will complete a non-brokered private placement offering of common shares (“Common Shares”) of <em>Indiva</em> whereby Canopy Growth will subscribe for 37,230,000 Common Shares for an aggregate",
"sentiment": 0.9246,
"highlighted_in": "main_text"
},
{
"highlight": "The balance of the consideration will be paid by Canopy to <em>Indiva</em> as follows: (i) additional consideration representing a value of $844,383; (ii) a cash payment of $1,250,000 on May 30, 2024.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Following the closing of the Private Placement, Canopy Growth will have the ability to nominate an individual as a Board observer on the Board of Directors of <em>Indiva</em>. Canopy Growth and <em>Indiva</em> will also enter into a customary standstill and voting support agreement.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "Canopy Growth and its affiliates do not currently own any convertible securities of <em>Indiva</em>.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "ABOUT <em>INDIVA</em>\n\n<em>Indiva</em> is proud to be Canada’s #1 producer of cannabis edibles. We set the gold standard for quality and innovation with our award-winning products, across a wide range of brands including Wana, Bhang, Pearls by Grön, as well as <em>Indiva</em> branded edibles and extracts.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Indiva</em> manufactures its top-quality products in its state-of-the-art facility in London, Ontario, and has a corporate workforce remotely distributed across Southern Ontario. Click here to connect with <em>Indiva</em> on LinkedIn, Instagram, Twitter and Facebook, and here to find more information on <em>Indiva</em> and its products.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Canopy Growth Corporation (CGC) And <em>Indiva</em> Inc. Announce Agreement",
"sentiment": 0.7003,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "dd76ecf2-c0ca-46ba-9dd6-090a7c1abc6e",
"title": "Brain Health Supplements Market (Product, Dosage Form) - Reach $14.24Bn by 2028 at 11.7% CAGR with Natural Molecules Segment Driving Growth During 2022–2028 | The Insight Partners",
"description": "The global brain health supplements market growth is driven by the growing prevalence of major depressive disorder (MDD) and increasing demand for brain...",
"keywords": "The Insight Partners, Brain health supplements, memory enhancement, PTSD, anxiety, depression, mental health, brain supplement, Nootropic, Health Supplement",
"snippet": "New York, May 30, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research report on \" Brain Health Supplements Market Size Report, Share, Growth...",
"url": "https://www.globenewswire.com/news-release/2023/05/30/2678246/0/en/Brain-Health-Supplements-Market-Product-Dosage-Form-Reach-14-24Bn-by-2028-at-11-7-CAGR-with-Natural-Molecules-Segment-Driving-Growth-During-2022-2028-The-Insight-Partners.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/efd8c9da-ac10-487a-a083-ec8f33cad35e",
"language": "en",
"published_at": "2023-05-30T11:33:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "UL",
"name": "Unilever PLC",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 19.832495,
"sentiment_score": 0.353833,
"highlights": [
{
"highlight": "., Natural Factors, <em>Unilever</em> <em>PLC</em>, Peak Nootropics, Purelife Bioscience Co., Ltd., Quincy Bioscience, Procera Health, and Harbin Pharmaceutical Group Co., Ltd. are key companies operating in the global brain health supplements market.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, <em>Unilever</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PLC</em>, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, Harbin Pharmaceutical Group Co., Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UN",
"name": "Unilever PLC",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 19.832495,
"sentiment_score": 0.353833,
"highlights": [
{
"highlight": "., Natural Factors, <em>Unilever</em> <em>PLC</em>, Peak Nootropics, Purelife Bioscience Co., Ltd., Quincy Bioscience, Procera Health, and Harbin Pharmaceutical Group Co., Ltd. are key companies operating in the global brain health supplements market.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, <em>Unilever</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PLC</em>, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, Harbin Pharmaceutical Group Co., Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UL.BA",
"name": "Unilever PLC",
"exchange": "BCBA",
"exchange_long": "Buenos Aires Stock Exchange",
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 19.830471,
"sentiment_score": 0.353833,
"highlights": [
{
"highlight": "., Natural Factors, <em>Unilever</em> <em>PLC</em>, Peak Nootropics, Purelife Bioscience Co., Ltd., Quincy Bioscience, Procera Health, and Harbin Pharmaceutical Group Co., Ltd. are key companies operating in the global brain health supplements market.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, <em>Unilever</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PLC</em>, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, Harbin Pharmaceutical Group Co., Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ULVR.PR",
"name": "Unilever PLC",
"exchange": "PSE",
"exchange_long": "Prague Stock Exchange",
"country": "cz",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 19.829777,
"sentiment_score": 0.353833,
"highlights": [
{
"highlight": "., Natural Factors, <em>Unilever</em> <em>PLC</em>, Peak Nootropics, Purelife Bioscience Co., Ltd., Quincy Bioscience, Procera Health, and Harbin Pharmaceutical Group Co., Ltd. are key companies operating in the global brain health supplements market.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, <em>Unilever</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PLC</em>, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, Harbin Pharmaceutical Group Co., Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "UNLYF",
"name": "Unilever PLC",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 19.827934,
"sentiment_score": 0.353833,
"highlights": [
{
"highlight": "., Natural Factors, <em>Unilever</em> <em>PLC</em>, Peak Nootropics, Purelife Bioscience Co., Ltd., Quincy Bioscience, Procera Health, and Harbin Pharmaceutical Group Co., Ltd. are key companies operating in the global brain health supplements market.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, <em>Unilever</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>PLC</em>, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, Harbin Pharmaceutical Group Co., Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "600664.SS",
"name": "Harbin Pharmaceutical Group Co., Ltd.",
"exchange": "SSE",
"exchange_long": "Shanghai Stock Exchange",
"country": "cn",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.194427,
"sentiment_score": 0.3607,
"highlights": [
{
"highlight": "., Quincy Bioscience, Procera Health, and <em>Harbin</em> <em>Pharmaceutical</em> <em>Group</em> <em>Co</em>., <em>Ltd</em>. are key companies operating in the global brain health supplements market. Leading players focus on expanding and diversifying their market presence and clientele, thereby tapping prevailing business opportunities.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered Danone SA, Health Via Modern Nutrition Inc., LIQUID HEALTH, INC., Natural Factors, Unilever PLC, Peak Nootropics, Purelife bioscience Co., Ltd., Quincy Bioscience, Procera Health, <em>Harbin</em>",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pharmaceutical</em> <em>Group</em> <em>Co</em>., <em>Ltd</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "0ba44a14-4e31-4832-95ef-32550971c68d",
"title": "Golden Grail Beverages (OTC: GOGY) Brings Spider Energy Drinks to Consumers at Grocery Outlet Stores Across the Country",
"description": "FORT LAUDERDALE, Fla., May 30, 2023 /PRNewswire/ -- Golden Grail Technology, operating as Golden Grail Beverages , proudly announces its partnership with Grocery Outlet, making Spider Energy drinks... | May 30, 2023",
"keywords": "GOLN GRAI stock exchange, news, information, press release, fort, may, 2023, golden, grail, operating, as, beverages, proudly, announces, its, partnership, with, grocery, making, spider, energy | GOGY | US38105V1052",
"snippet": "FORT LAUDERDALE, Fla., May 30, 2023 /PRNewswire/ -- Golden Grail Technology, operating as Golden Grail Beverages (OTC: GOGY), proudly announces its partnership ...",
"url": "https://www.marketscreener.com/quote/stock/GOLN-GRAI-19777553/news/Golden-Grail-Beverages-OTC-GOGY-Brings-Spider-Energy-Drinks-to-Consumers-at-Grocery-Outlet-Stores-43988992/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2023-05-30T12:31:07.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "HEMP",
"name": "Hemp, Inc",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.577686,
"sentiment_score": 0.836,
"highlights": [
{
"highlight": "Our robust product offerings include Sway Energy Drink, Spider Energy Drink, Trevi Fruit Essence Water, Tickle Water, Sketch Can for Tweens, Cause Water & KOZ Water helping reduce global plastic pollution and Scorpion Energy <em>Hemp</em>/CBD.",
"sentiment": 0.836,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "c05236d9-ef4a-4341-bcd4-748b4e64a42b",
"title": "Golden Grail Beverages (OTC: GOGY) Brings Spider Energy Drinks to Consumers at Grocery Outlet Stores Across the Country",
"description": "/PRNewswire/ -- Golden Grail Technology, operating as Golden Grail Beverages (OTC: GOGY), proudly announces its partnership with Grocery Outlet, making Spider...",
"keywords": "Golden Grail Technology Corp",
"snippet": "FORT LAUDERDALE, Fla., May 30, 2023 /PRNewswire/ -- Golden Grail Technology, operating as Golden Grail Beverages (OTC: GOGY), proudly announces its partnership ...",
"url": "https://www.prnewswire.com/news-releases/golden-grail-beverages-otc-gogy-brings-spider-energy-drinks-to-consumers-at-grocery-outlet-stores-across-the-country-301836873.html",
"image_url": "https://www.prnewswire.com/content/dam/prnewswire/icons/2019-Q4-PRN-Icon-32-32.png",
"language": "en",
"published_at": "2023-05-30T12:30:00.000000Z",
"source": "prnewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "GOGY",
"name": "Golden Grail Technology Corp.",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 132.86452,
"sentiment_score": 0.453025,
"highlights": [
{
"highlight": "., May 30, 2023 /PRNewswire/ -- <em>Golden</em> <em>Grail</em> <em>Technology</em>, operating as Golden Grail Beverages (<em>OTC</em>: <em>GOGY</em>), proudly announces its partnership with Grocery Outlet, making Spider Energy drinks available to consumers across the country.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "To learn more about Golden Grail Beverages and Spider Energy drinks, visit https://spiderenergy.com/\n\nGolden Grail Beverages (<em>OTC</em>: <em>GOGY</em>) www.GoldenGrailBeverages.com is a fast-growing company with a strategic mission to innovate, build and streamline the growth of its beverage portfolio through fiscally responsible investing.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "SOURCE <em>Golden</em> <em>Grail</em> <em>Technology</em> <em>Corp</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Golden Grail Beverages (<em>OTC</em>: <em>GOGY</em>) Brings Spider Energy Drinks to Consumers at Grocery Outlet Stores Across the Country",
"sentiment": 0.2732,
"highlighted_in": "title"
}
]
},
{
"symbol": "HEMP",
"name": "Hemp, Inc",
"exchange": "OTC",
"exchange_long": "Over-the-counter Markets",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.7966,
"sentiment_score": 0.836,
"highlights": [
{
"highlight": "Our robust product offerings include Sway Energy Drink, Spider Energy Drink, Trevi Fruit Essence Water, Tickle Water, Sketch Can for Tweens, Cause Water & KOZ Water helping reduce global plastic pollution and Scorpion Energy <em>Hemp</em>/CBD.",
"sentiment": 0.836,
"highlighted_in": "main_text"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 670,
"sentiment_avg": 0.19629011757793757
}
]
}
Other details
Entity count
- 12,299